Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

This study is testing ropeginterferon alfa-2b (P1101), a long-acting immune-stimulating injection given every two weeks, for people with cutaneous T-cell lymphoma (CTCL) — a type of skin cancer involving immune cells — that has not responded adequately to standard skin-directed treatments. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of CTCL (including mycosis fungoides, Sézary syndrome, or lymphomatoid papulosis) - For early-stage (IA-IB): you have failed at least two prior skin-directed therapies - For later stages (IIA-IIIB): your cancer did not fully respond to phototherapy, extracorporeal photopheresis, or at least 2 topical therapies - Your thyroid function is normal or well-controlled - You have adequate blood counts and kidney/liver function **You may NOT be eligible if...** - Your cancer has large cell transformation (a more aggressive change in the tumor) - You have had systemic cancer treatment less than 3 weeks before starting the study - You are pregnant or breastfeeding - You have uncontrolled very high triglycerides or cholesterol - You cannot tolerate subcutaneous (under-skin) injections Talk to your doctor to see if this trial is right for you.